Program
ASP2246
A development code.
Its studies are mostly in Ischemic Stroke, led by Astellas Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 11 open or running | phase 2since Jan 4, 2026 | Jan 4, 2026 | Feb 28, 2030phase 2 · NCT07318714 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 4, 2026First study: phase 2 study in Chronic Ischemic StrokeFirst studyNCT07318714 · 84 planned · Japan
Ahead
- Feb 28, 2030Primary completion: phase 2 study in Chronic Ischemic StrokeNCT07318714
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07318714Chronic Ischemic Stroke · Japan | 2 | Recruiting | Feb 28, 2030 | 84 |
How it is read
Names in the registry
- “ASP2246”, 1 entry
Codes read as this program: ASP2246.
Conditions, from the studies’ own filings
- Ischemic Stroke, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.